<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09-PONE-RA-08226R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0005469</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Genetics and Genomics/Genetics of Disease</subject><subject>Genetics and Genomics/Population Genetics</subject><subject>Diabetes and Endocrinology/Type 2 Diabetes</subject></subj-group></article-categories><title-group><article-title>Variation in <italic>CHI3LI</italic> in Relation to Type 2 Diabetes and Related Quantitative Traits</article-title><alt-title alt-title-type="running-head">YKL-40 in Type 2 Diabetes</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Rathcke</surname><given-names>Camilla Noelle</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author"><name><surname>Holmkvist</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>J&#x000f8;rgensen</surname><given-names>Torben</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Borch-Johnsen</surname><given-names>Knut</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Hansen</surname><given-names>Torben</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Pedersen</surname><given-names>Oluf Borbye</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Vestergaard</surname><given-names>Henrik</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Department of Endocrinology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Hagedorn Research Institute, Gentofte, Denmark</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Research Centre for Prevention and Health, Glostrup Hospital, University of Copenhagen, Copenhagen, Denmark</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Steno Diabetes Center, Gentofte, Denmark</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Faculty of Health Sciences, University of Aarhus, Aarhus, Denmark</addr-line></aff><aff id="aff6"><label>6</label><addr-line>Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Vella</surname><given-names>Adrian</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Mayo Clinic College of Medicine, United States of America</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>cnr@dadlnet.dk</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: CNR TJ KBJ TH OBP HV. Performed the experiments: CNR TJ KBJ TH OBP HV. Analyzed the data: CNR JH. Contributed reagents/materials/analysis tools: CNR JH TH HV. Wrote the paper: CNR. Critical revision of the manuscript: JH TJ KBJ TH OBP HV.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>7</day><month>5</month><year>2009</year></pub-date><volume>4</volume><issue>5</issue><elocation-id>e5469</elocation-id><history><date date-type="received"><day>19</day><month>1</month><year>2009</year></date><date date-type="accepted"><day>29</day><month>3</month><year>2009</year></date></history><copyright-statement>Rathcke et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><sec><title>Background</title><p><italic>CHI3LI</italic> encoding the inflammatory glycoprotein YKL-40 is located on chromosome 1q32.1. YKL-40 is involved in inflammatory processes and patients with Type 2 Diabetes (T2D) have elevated circulating YKL-40 levels which correlate with their level of insulin resistance. Interestingly, it has been reported that rs10399931 (&#x02212;329 G/A) of <italic>CHI3LI</italic> contributes to the inter-individual plasma YKL-40 levels in patients with sarcoidosis, and that rs4950928 (&#x02212;131 C/G) is a susceptibility polymorphism for asthma and a decline in lung function. We hypothesized that single nucleotide polymorphisms (SNPs) or haplotypes thereof the <italic>CHI3LI</italic> locus might influence risk of T2D. The aim of the present study was to investigate the putative association between SNPs and haplotype blocks of <italic>CHI3LI</italic> and T2D and T2D related quantitative traits.</p></sec><sec><title>Methods/Principal Findings</title><p>Eleven SNPs of <italic>CHI3LI</italic> were genotyped in 6514 individuals from the Inter99 cohort and 2924 individuals from the outpatient clinic at Steno Diabetes Center. In cas-control studies a total of 2345 T2D patients and 5302 individuals with a normal glucose tolerance test were examined.</p><p>We found no association between rs10399931 (OR, 0.98 (CI, 0.88&#x02013;1.10), p&#x0200a;&#x0003d;&#x0200a;0.76), rs4950928 (0.98 (0.87&#x02013;1.10), p&#x0200a;&#x0003d;&#x0200a;0.68) or any of the other SNPs with T2D. Similarly, we found no significant association between any of the 11 tgSNPs and T2D related quantitative traits, all p&#x0003e;0.14. None of the identified haplotype blocks of <italic>CHI3LI</italic> showed any association with T2D, all p&#x0003e;0.16.</p></sec><sec><title>Conclusions/Significance</title><p>None of the examined SNPs or haplotype blocks of <italic>CHI3LI</italic> showed any association with T2D or T2D related quantitative traits. Estimates of insulin resistance and dysregulated glucose homeostasis in T2D do not seem to be accounted for by the examined variations of <italic>CHI3LI</italic>.</p></sec></abstract><counts><page-count count="7"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The primary molecular defects in Type 2 diabetes (T2D) remain largely unknown, but it is widely recognized that both genetic and environmental risk factors have interacting roles in the pathogenesis and the progression of the disease. However, recent discoveries have led to a progress in the understanding of the molecular genetic background of T2D brought forward by genome-wide association (GWA) studies which have dramatically increased the number of validated type 2 diabetes loci with modest impact on relative diabetes risk <xref ref-type="bibr" rid="pone.0005469-McCarthy1">&#x0005b;1&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005469-McCarthy3">&#x0005b;3&#x0005d;</xref>. Several loci of interest may be located in the region of human chromosone 1q21&#x02013;24 which shows replicated linkage to T2D in at least eight populations including North European Caucasian families, Pima Indians and Old Order Amish <xref ref-type="bibr" rid="pone.0005469-McCarthy1">&#x0005b;1&#x0005d;</xref>. Furthermore, linkage analysis has also provided evidence for linkage of the metabolic syndrome (central obesity, dyslipidemia, hyperglycemia and hypertension) to 1q23&#x02013;31 <xref ref-type="bibr" rid="pone.0005469-Langefeld1">&#x0005b;4&#x0005d;</xref>. These regions as well as other closely related regions of chromosome 1 are under intense search for identification of T2D susceptibility genes.</p><p>Chitinase 3-like 1 (<italic>CHI3LI</italic>) encoding the inflammatory glycoprotein YKL-40 is located in a phylogenetically highly conserved area on chromosome 1q32.1. YKL-40 is involved in inflammatory processes and extracellular matrix remodelling including angiogenesis and functions as a growth factor for several cell types <xref ref-type="bibr" rid="pone.0005469-Rathcke1">&#x0005b;5&#x0005d;</xref>. Studies have shown, that patients with T2D have elevated plasma YKL-40 levels <xref ref-type="bibr" rid="pone.0005469-Rathcke2">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005469-Rathcke3">&#x0005b;7&#x0005d;</xref> which correlate with insulin resistance and with their diabetic lipid profile, but not with estimates of glycemic regulation <xref ref-type="bibr" rid="pone.0005469-Rathcke2">&#x0005b;6&#x0005d;</xref>. Also patients with type 1 diabetes (T1D) have elevated YKL-40 levels which increase with increasing levels of albuminuria <xref ref-type="bibr" rid="pone.0005469-Rathcke4">&#x0005b;8&#x0005d;</xref>.</p><p>The <italic>CHI3LI</italic> promotor variant &#x02212;329 G/A (rs10399931) associates with the inter-individual plasma YKL-40 levels in patients with sarcoidosis <xref ref-type="bibr" rid="pone.0005469-Kruit1">&#x0005b;9&#x0005d;</xref>. Furthermore, the functional <italic>CHI3LI</italic> promotor SNP &#x02212;131C&#x02192;G (rs4950928) increases the mRNA transcript levels coding for the YKL-40 protein in a genome wide study of gene expression in Epstein-Barr virus-transformed lymphoblastoid cells from children with asthma <xref ref-type="bibr" rid="pone.0005469-Dixon1">&#x0005b;10&#x0005d;</xref> and is shown to be predictive of asthma, bronchial hyperresponsiveness and reduced lung function <xref ref-type="bibr" rid="pone.0005469-Ober1">&#x0005b;11&#x0005d;</xref>. Since <italic>CHI3LI</italic> is a susceptibility gene for asthma with elevated circulating YKL-40 levels as a biomarker, it is possible that one of these single nucleotide polymorphisms (SNPs) or another gene variation with which they could be in tight linkage disequilibrium with may be functional in relation to T2D.</p><p>Applying a HapMap&#x02013;based tgSNP approach the objective of the present study was to investigate the putative association of common variation in the <italic>CHI3LI</italic> locus with T2D, obesity and several T2D associated quantitative traits.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><sec id="s2a"><title>Ethics Statement</title><p>Informed written consent was obtained from all participants before participation. The study was approved by the Ethical Committees of Copenhagen and Aarhus and was in accordance with the principle of the Helsinki Declaration II.</p></sec><sec id="s2b"><title>Study population</title><p>A total of 11 tgSNPs (including the rs10399931 and rs4950928) covering all haplotype blocks in <italic>CHI3LI</italic> locus was genotyped. Genotyping was performed in 9438 individuals including Inter99, a population-based sample of unrelated, middle-aged Danish individuals living in the greater Copenhagen area, and 2924 individuals recruited from the outpatient clinic at Steno Diabetes Center.</p><p>The Inter99 study population has been described in detail previously <xref ref-type="bibr" rid="pone.0005469-Jorgensen1">&#x0005b;12&#x0005d;</xref>. In brief, both participants from the Inter99 cohort and individuals recruited from the outpatient clinic were characterized by an oral glucose tolerance test (OGTT). Impaired glucose homeostasis (IFG, IGT and diabetes) was defined according to WHO criteria after a 75 g OGTT <xref ref-type="bibr" rid="pone.0005469-Alberti1">&#x0005b;13&#x0005d;</xref> giving a classification of normal glucose tolerance (NGT; n&#x0200a;&#x0003d;&#x0200a;5302), impaired fasting glycemia (IFG; n&#x0200a;&#x0003d;&#x0200a;540), impaired glucose tolerance (IGT; n&#x0200a;&#x0003d;&#x0200a;830) or screen-detected untreated T2D (SDU DM; n&#x0200a;&#x0003d;&#x0200a;294). Missing data was seen in 421 individuals (4.5&#x00025;) and a total of 2091 individuals had known T2D. The participants were investigated for an association between genotype and quantitative metabolic traits; individuals with known type 2 diabetes were excluded from these analyses. All participants were of Danish nationality.</p></sec><sec id="s2c"><title>Biochemical and anthropometric measurements</title><p>Height and body weight were measured in light indoor clothes and without shoes, and BMI was calculated as weight (kg) divided by (height (m))<sup>2</sup>. Waist circumference was measured in the standing position midway between the iliac crest and the lower costal margin and hip circumference at its maximum.</p><p>In both Inter99- and Steno Diabetes Center participants, blood samples were drawn in the fasting state after a 12-h overnight fast. Plasma glucose was analysed by a glucose oxidase method (Granutest, Merck, Darmstadt, Germany). HbA<sub>1C</sub> was measured by ion-exchange high performance liquid chromatography (normal reference range: 4.1&#x02013;6.4&#x00025;) and serum insulin (excluding des(31, 32) and intact proinsulin) was measured using the AutoDELFIA insulin kit (Perkin-Elmer/Wallac, Turku, Finland). Serum C-peptide concentrations were measured by a time-resolved fluoroimmunoassay (AutoDELFIA C-peptide kit; Perkin-Elmer/Wallac, Turku, Finland).</p><p>Serum triglyceride and total and HDL-cholesterol were analysed using enzymatic colorimetric methods (GPO-PAP and CHOD-PAP, Roche Molecular Biochemicals, Mannheim, Germany). HOMA-IR was calculated as fasting plasma glucose &#x0005b;mmol/l&#x0005d; multiplied by fasting serum insulin &#x0005b;pmol/l&#x0005d; and divided by 22.5. Insulinogenic index at 30 min was calculated as fasting serum insulin subtracted from plasma insulin at 30 min &#x0005b;pmol/l&#x0005d; divided by plasma glucose at 30 min &#x0005b;mmol/l&#x0005d;.</p></sec><sec id="s2d"><title>Genotyping</title><p>SNPs in a region 22 kb upstream and 10 kb downstream of <italic>CHI3LI</italic> were chosen from the HapMap project (<ext-link ext-link-type="uri" xlink:href="http://www.hapmap.org">www.hapmap.org</ext-link>). Haplotype tgSNPs were selected from the HapMap data using TAGGER <xref ref-type="bibr" rid="pone.0005469-deBakker1">&#x0005b;14&#x0005d;</xref>. TAGGER was used with a 5&#x00025; MAF cut off, agressive tagging (r<sup>2</sup>&#x0003e;0.8). Two haplotype blocks with 2 and 5 SNPs, respectively, and with similar structures in both patients with T2D and in controls were identified (<xref ref-type="fig" rid="pone-0005469-g001">Figure 1</xref>). The other tgSNPs were not included in the haplotype block analyses since they were not part of any block. Genotyping was performed using TaqMan allelic discrimination (Kbioscience, Herts, UK) with a success rate &#x0003e;97.0&#x00025;. Discordance was 0&#x00025; as judged from re-genotyping of 965 random duplicate samples. Genotype distribution obeyed Hardy Weinberg Equilibrium (HWE), all p&#x0003e;0.25.</p><fig id="pone-0005469-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005469.g001</object-id><label>Figure 1</label><caption><title>Linkage disequilibrium (LD) pattern of the investigated variations of <italic>CHI3L1</italic>.</title></caption><graphic xlink:href="pone.0005469.g001"/></fig></sec><sec id="s2e"><title>Statistical analyses</title><p>Logistic regression analyses were used to analyse differences in allele and genotype frequencies between case and control subjects; analyses were adjusted for age, sex and BMI where appropriate. The statistical analyses were performed using RGui version 2.5.0 (available at <ext-link ext-link-type="uri" xlink:href="http://www.r-project.org">http://www.r-project.org</ext-link>). The haplotype block analyses were analysed for an association with T2D after adjustment for age, sex and BMI. Haplotype analyses were performed using PLINK <xref ref-type="bibr" rid="pone.0005469-Purcell1">&#x0005b;15&#x0005d;</xref>. P-values are not adjusted for multiple testing.</p></sec></sec><sec id="s3"><title>Results</title><p>Clinical characteristics for the Inter99 cohort and the individuals recruited at Steno Diabetes Center are presented in <xref ref-type="table" rid="pone-0005469-t001">Table 1</xref>. A total of 2345 T2D patients and 5302 individuals with a normal glucose tolerance test were identified.</p><table-wrap id="pone-0005469-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005469.t001</object-id><label>Table 1</label><caption><title>Clinical data for study sample.</title></caption><graphic id="pone-0005469-t001-1" xlink:href="pone.0005469.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005469-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Complete sample</td><td align="left" rowspan="1" colspan="1">SDC sample</td><td align="left" rowspan="1" colspan="1">Inter99 cohort</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">N (m/w)</td><td align="left" rowspan="1" colspan="1">9438 (4834/4604)</td><td align="left" rowspan="1" colspan="1">2924 (1665/1259)</td><td align="left" rowspan="1" colspan="1">6514 (3169/3345)</td></tr><tr><td align="left" rowspan="1" colspan="1">NGT</td><td align="left" rowspan="1" colspan="1">5302 (2456/2846)</td><td align="left" rowspan="1" colspan="1">734 (334/400)</td><td align="left" rowspan="1" colspan="1">4568 (2122/2446)</td></tr><tr><td align="left" rowspan="1" colspan="1">IFG</td><td align="left" rowspan="1" colspan="1">540 (391/149)</td><td align="left" rowspan="1" colspan="1">32 (18/14)</td><td align="left" rowspan="1" colspan="1">508 (373/135)</td></tr><tr><td align="left" rowspan="1" colspan="1">IGT</td><td align="left" rowspan="1" colspan="1">830 (414/416)</td><td align="left" rowspan="1" colspan="1">123 (66/57)</td><td align="left" rowspan="1" colspan="1">707 (348/359)</td></tr><tr><td align="left" rowspan="1" colspan="1">SDU DM</td><td align="left" rowspan="1" colspan="1">294 (187/107)</td><td align="left" rowspan="1" colspan="1">39 (27/12)</td><td align="left" rowspan="1" colspan="1">255 (160/95)</td></tr><tr><td align="left" rowspan="1" colspan="1">Known DM</td><td align="left" rowspan="1" colspan="1">2051 (1259/801)</td><td align="left" rowspan="1" colspan="1">1946 (1200/755)</td><td align="left" rowspan="1" colspan="1">105 (59/46)</td></tr><tr><td align="left" rowspan="1" colspan="1">NGT age (years)</td><td align="left" rowspan="1" colspan="1">47&#x000b1;9</td><td align="left" rowspan="1" colspan="1">58&#x000b1;9</td><td align="left" rowspan="1" colspan="1">45&#x000b1;8</td></tr><tr><td align="left" rowspan="1" colspan="1">NGT BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">25.6&#x000b1;9.1</td><td align="left" rowspan="1" colspan="1">25.9&#x000b1;8.7</td><td align="left" rowspan="1" colspan="1">25.5&#x000b1;4.1</td></tr><tr><td align="left" rowspan="1" colspan="1">T2D age (years)</td><td align="left" rowspan="1" colspan="1">60&#x000b1;12</td><td align="left" rowspan="1" colspan="1">62&#x000b1;11</td><td align="left" rowspan="1" colspan="1">51&#x000b1;7</td></tr><tr><td align="left" rowspan="1" colspan="1">T2D BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">30.1&#x000b1;5.5</td><td align="left" rowspan="1" colspan="1">30.0&#x000b1;5.5</td><td align="left" rowspan="1" colspan="1">30.4&#x000b1;5.6</td></tr><tr><td align="left" rowspan="1" colspan="1">T2D HbA1c (&#x00025;)</td><td align="left" rowspan="1" colspan="1">7.8&#x000b1;1.7</td><td align="left" rowspan="1" colspan="1">8.1&#x000b1;1.6</td><td align="left" rowspan="1" colspan="1">7.1&#x000b1;1.7</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>Data is mean&#x000b1;S.D. SDC, Steno Diabetes Center; N (m/w), number (men/women); NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; SDU DM, screen detected untreated diabetes mellitus; T2D, Type 2 diabetes; BMI, Body Mass Index; HbA1c, hemoglobin A1c.</p></fn></table-wrap-foot></table-wrap><p>Overall we found no association of rs10399931, rs4950928 or any of the other tgSNPs of <italic>CHI3LI</italic> with T2D after adjustment for age, sex, BMI and glucose tolerance, all p&#x0003e;0.25 (<xref ref-type="table" rid="pone-0005469-t002">Table 2</xref>). In similar analyses, none of the tgSNPs were associated with impaired fasting glucose (IFG) or impaired glucose tolerance (IGT), although a borderline protective association with IGT was detected for rs12123883 (<xref ref-type="supplementary-material" rid="pone.0005469.s001">Table S1</xref> and <xref ref-type="supplementary-material" rid="pone.0005469.s002">S2</xref>).</p><table-wrap id="pone-0005469-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005469.t002</object-id><label>Table 2</label><caption><title>Case control association studies of 2345 T2D patients and 5302 glucose tolerant control participants in relation to the 11 tgSNPs of <italic>CHI3LI</italic>.</title></caption><graphic id="pone-0005469-t002-2" xlink:href="pone.0005469.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005469-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNP</td><td align="left" rowspan="1" colspan="1">Allele</td><td align="left" rowspan="1" colspan="1">MAF</td><td align="left" rowspan="1" colspan="1">Genotype</td><td colspan="2" align="left" rowspan="1">Genotype distribution</td><td align="left" rowspan="1" colspan="1">Additive model</td><td align="left" rowspan="1" colspan="1">p value</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">(major/minor)</td><td align="left" rowspan="1" colspan="1">(&#x00025;)</td><td align="left" rowspan="1" colspan="1">All</td><td align="left" rowspan="1" colspan="1">NGT, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">T2D, n (&#x00025;)</td><td align="left" rowspan="1" colspan="1">OR (CI)</td><td align="left" rowspan="1" colspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs883125</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">15.6</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">3546 (71.8)</td><td align="left" rowspan="1" colspan="1">1574 (71.0)</td><td align="left" rowspan="1" colspan="1">0.98 (0.86&#x02013;1.12)</td><td align="left" rowspan="1" colspan="1">0.78</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CG</td><td align="left" rowspan="1" colspan="1">1280 (25.9)</td><td align="left" rowspan="1" colspan="1">591 (26.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">114 (2.3)</td><td align="left" rowspan="1" colspan="1">51 (2.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs880633</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">46.3</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">1470 (30.0)</td><td align="left" rowspan="1" colspan="1">645 (29.4)</td><td align="left" rowspan="1" colspan="1">1.00 (0.90&#x02013;1.10)</td><td align="left" rowspan="1" colspan="1">0.96</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">2416 (49.3)</td><td align="left" rowspan="1" colspan="1">1077 (48.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">1018 (20.7)</td><td align="left" rowspan="1" colspan="1">483 (21.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs4950928</td><td align="left" rowspan="1" colspan="1">C/G</td><td align="left" rowspan="1" colspan="1">20.4</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">3159 (63.6)</td><td align="left" rowspan="1" colspan="1">1402 (63.4)</td><td align="left" rowspan="1" colspan="1">0.98 (0.87&#x02013;1.10)</td><td align="left" rowspan="1" colspan="1">0.68</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CG</td><td align="left" rowspan="1" colspan="1">1612 (32.4)</td><td align="left" rowspan="1" colspan="1">716 (32.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">197 (4.0)</td><td align="left" rowspan="1" colspan="1">93 (4.2)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs10399931</td><td align="left" rowspan="1" colspan="1">C/T</td><td align="left" rowspan="1" colspan="1">23.7</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">2894 (58.8)</td><td align="left" rowspan="1" colspan="1">1287 (58.4)</td><td align="left" rowspan="1" colspan="1">0.98 (0.88&#x02013;1.10)</td><td align="left" rowspan="1" colspan="1">0.76</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">1754 (35.6)</td><td align="left" rowspan="1" colspan="1">791 (35.9)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">273 (5.6)</td><td align="left" rowspan="1" colspan="1">126 (5.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs6691378</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">12.6</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">3840 (77.7)</td><td align="left" rowspan="1" colspan="1">1690 (76.4)</td><td align="left" rowspan="1" colspan="1">1.08 (0.94&#x02013;1.25)</td><td align="left" rowspan="1" colspan="1">0.29</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GA</td><td align="left" rowspan="1" colspan="1">1030 (20.9)</td><td align="left" rowspan="1" colspan="1">487 (22.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">69 (1.4)</td><td align="left" rowspan="1" colspan="1">34 (1.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs4950930</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">4.0</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">4512 (91.6)</td><td align="left" rowspan="1" colspan="1">2053 (92.5)</td><td align="left" rowspan="1" colspan="1">0.96 (0.76&#x02013;1.20)</td><td align="left" rowspan="1" colspan="1">0.70</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GA</td><td align="left" rowspan="1" colspan="1">399 (8.1)</td><td align="left" rowspan="1" colspan="1">157 (7.1)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">13 (0.3)</td><td align="left" rowspan="1" colspan="1">10 (0.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs12123883</td><td align="left" rowspan="1" colspan="1">T/C</td><td align="left" rowspan="1" colspan="1">7.4</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">4235 (85.5)</td><td align="left" rowspan="1" colspan="1">1906 (85.7)</td><td align="left" rowspan="1" colspan="1">0.95 (0.79&#x02013;1.14)</td><td align="left" rowspan="1" colspan="1">0.58</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">TC</td><td align="left" rowspan="1" colspan="1">684 (13.8)</td><td align="left" rowspan="1" colspan="1">305 (13.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">37 (0.7)</td><td align="left" rowspan="1" colspan="1">13 (5.8)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs2486064</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">42.3</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">1636 (33.0)</td><td align="left" rowspan="1" colspan="1">742 (33.7)</td><td align="left" rowspan="1" colspan="1">0.97 (0.87&#x02013;1.07)</td><td align="left" rowspan="1" colspan="1">0.48</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GA</td><td align="left" rowspan="1" colspan="1">2406 (48.6)</td><td align="left" rowspan="1" colspan="1">1057 (48.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">909 (18.4)</td><td align="left" rowspan="1" colspan="1">402 (18.3)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs2886117</td><td align="left" rowspan="1" colspan="1">G/A</td><td align="left" rowspan="1" colspan="1">12.9</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">3809 (76.6)</td><td align="left" rowspan="1" colspan="1">1679 (75.8)</td><td align="left" rowspan="1" colspan="1">1.04 (0.90&#x02013;1.20)</td><td align="left" rowspan="1" colspan="1">0.59</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GA</td><td align="left" rowspan="1" colspan="1">1078 (21.7)</td><td align="left" rowspan="1" colspan="1">500 (22.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">84 (1.7)</td><td align="left" rowspan="1" colspan="1">36 (1.6)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs872129</td><td align="left" rowspan="1" colspan="1">A/G</td><td align="left" rowspan="1" colspan="1">7.2</td><td align="left" rowspan="1" colspan="1">AA</td><td align="left" rowspan="1" colspan="1">4183 (84.5)</td><td align="left" rowspan="1" colspan="1">1910 (86.1)</td><td align="left" rowspan="1" colspan="1">0.91 (0.76&#x02013;1.09)</td><td align="left" rowspan="1" colspan="1">0.32</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AG</td><td align="left" rowspan="1" colspan="1">730 (14.8)</td><td align="left" rowspan="1" colspan="1">298 (13.4)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">35 (0.7)</td><td align="left" rowspan="1" colspan="1">11 (0.5)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">rs871799</td><td align="left" rowspan="1" colspan="1">G/C</td><td align="left" rowspan="1" colspan="1">9.2</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">4028 (81.3)</td><td align="left" rowspan="1" colspan="1">1821 (82.3)</td><td align="left" rowspan="1" colspan="1">0.96 (0.81&#x02013;1.13)</td><td align="left" rowspan="1" colspan="1">0.60</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GC</td><td align="left" rowspan="1" colspan="1">873 (17.6)</td><td align="left" rowspan="1" colspan="1">376 (17.0)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">54 (1.1)</td><td align="left" rowspan="1" colspan="1">16 (0.7)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="nt102"><p>T2D, type 2 diabetes; SNP, single nucleotide polymorphism; MAF, minor allele frequency; NGT, normal glucose tolerance; OR (CI), odds ratio (confidence interval).</p></fn></table-wrap-foot></table-wrap><p><xref ref-type="table" rid="pone-0005469-t003">Table 3</xref> and <xref ref-type="table" rid="pone-0005469-t004">4</xref> show the multiadjusted association of rs10399931 and rs4950928 with BMI and other T2D related quantitative traits among NGT, IFG, IGT and screen-detected untreated T2D in Inter99 and Steno Diabetes Center collected individuals. We found a significant association between rs10399931 and the serum C-peptide concentration after 2 hours, p&#x0200a;&#x0003d;&#x0200a;0.03, but in all we found no significant association between rs10399931 or rs4950928 and any of the T2D quantitative traits. Similarly, none of the other SNPs showed any associations (data not shown).</p><table-wrap id="pone-0005469-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005469.t003</object-id><label>Table 3</label><caption><title>Association of rs10399931 of <italic>CHI3LI</italic> and T2D related quantitative traits among NGT, IFG, IGT and screen-detected untreated T2D in Inter99 and Steno Diabetes Center collected individuals.</title></caption><graphic id="pone-0005469-t003-3" xlink:href="pone.0005469.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005469-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">TT</td><td align="left" rowspan="1" colspan="1">P<sub>add</sub></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Alleles</td><td align="left" rowspan="1" colspan="1">4782</td><td align="left" rowspan="1" colspan="1">2927</td><td align="left" rowspan="1" colspan="1">781</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">46&#x000b1;8</td><td align="left" rowspan="1" colspan="1">46&#x000b1;8</td><td align="left" rowspan="1" colspan="1">46&#x000b1;8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">26.2&#x000b1;4.5</td><td align="left" rowspan="1" colspan="1">26.2&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1">25.9&#x000b1;4</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Whratio</td><td align="left" rowspan="1" colspan="1">0.86&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.86&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.86&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.89</td></tr><tr><td align="left" rowspan="1" colspan="1">Waist (cm)</td><td align="left" rowspan="1" colspan="1">87&#x000b1;13</td><td align="left" rowspan="1" colspan="1">87&#x000b1;13</td><td align="left" rowspan="1" colspan="1">86&#x000b1;13</td><td align="left" rowspan="1" colspan="1">0.69</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" rowspan="1" colspan="1">172&#x000b1;9</td><td align="left" rowspan="1" colspan="1">172&#x000b1;9</td><td align="left" rowspan="1" colspan="1">172&#x000b1;9</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting serum triglyceride (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;1.5</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting serum cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">0.61</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting serum HDL cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic bp (mmHg)</td><td align="left" rowspan="1" colspan="1">130&#x000b1;17</td><td align="left" rowspan="1" colspan="1">131&#x000b1;17</td><td align="left" rowspan="1" colspan="1">131&#x000b1;17</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic bp (mmHg)</td><td align="left" rowspan="1" colspan="1">82&#x000b1;11</td><td align="left" rowspan="1" colspan="1">83&#x000b1;11</td><td align="left" rowspan="1" colspan="1">82&#x000b1;12</td><td align="left" rowspan="1" colspan="1">0.34</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma insulin (pmol/l)</td><td align="left" rowspan="1" colspan="1">42&#x000b1;28</td><td align="left" rowspan="1" colspan="1">42&#x000b1;27</td><td align="left" rowspan="1" colspan="1">41&#x000b1;27</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma insulin 30 min (pmol/l)</td><td align="left" rowspan="1" colspan="1">293&#x000b1;191</td><td align="left" rowspan="1" colspan="1">288&#x000b1;175</td><td align="left" rowspan="1" colspan="1">285&#x000b1;169</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma insulin 120 min (pmol/l)</td><td align="left" rowspan="1" colspan="1">217&#x000b1;217</td><td align="left" rowspan="1" colspan="1">215&#x000b1;203</td><td align="left" rowspan="1" colspan="1">224&#x000b1;208</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="left" rowspan="1" colspan="1">10.6&#x000b1;8.1</td><td align="left" rowspan="1" colspan="1">10.5&#x000b1;7.7</td><td align="left" rowspan="1" colspan="1">10.4&#x000b1;7.7</td><td align="left" rowspan="1" colspan="1">0.95</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulinogenic Index</td><td align="left" rowspan="1" colspan="1">30&#x000b1;20</td><td align="left" rowspan="1" colspan="1">29&#x000b1;19</td><td align="left" rowspan="1" colspan="1">29&#x000b1;18</td><td align="left" rowspan="1" colspan="1">0.75</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">0.84</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma glucose 30 min (mmol/l)</td><td align="left" rowspan="1" colspan="1">8.7&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">8.7&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">8.7&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">0.44</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma glucose 120 min (mmol/l)</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;2.2</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;2.2</td><td align="left" rowspan="1" colspan="1">6.3&#x000b1;2.1</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma C-peptide (pmol/l)</td><td align="left" rowspan="1" colspan="1">596&#x000b1;274</td><td align="left" rowspan="1" colspan="1">593&#x000b1;256</td><td align="left" rowspan="1" colspan="1">594&#x000b1;273</td><td align="left" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma C-peptide 30 min(pmol/l)</td><td align="left" rowspan="1" colspan="1">2006&#x000b1;736</td><td align="left" rowspan="1" colspan="1">1994&#x000b1;678</td><td align="left" rowspan="1" colspan="1">1977&#x000b1;732</td><td align="left" rowspan="1" colspan="1">0.86</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma C-peptide 120 min (pmol/l)</td><td align="left" rowspan="1" colspan="1">2305&#x000b1;1041</td><td align="left" rowspan="1" colspan="1">2315&#x000b1;980</td><td align="left" rowspan="1" colspan="1">2359&#x000b1;987</td><td align="left" rowspan="1" colspan="1">0.03</td></tr></tbody></table><table-wrap-foot><fn id="nt103"><p>Data presented as mean (SD). Analyses adjusted for age, gender, BMI, glucose tolerance (NGT, IFG, IGT and screen-detected untreated T2D).</p></fn><fn id="nt104"><p>T2D, type 2 diabetes; NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; add, additive; dom, dominant; res, recessive; bmi, body mass index; whratio, waist-to-hip ratio; hdl, high density lipoprotein; bp, blood pressure; HOMA-IR, insulin resistance according to HOMA model.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0005469-t004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005469.t004</object-id><label>Table 4</label><caption><title>Association of rs49509028 of <italic>CHI3LI</italic> and T2D related quantitative traits among NGT, IFG, IGT and screen-detected untreated T2D in Inter99 and Steno Diabetes Center collected individuals.</title></caption><graphic id="pone-0005469-t004-4" xlink:href="pone.0005469.t004"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005469-t004-4"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Genotype</td><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">CG</td><td align="left" rowspan="1" colspan="1">GG</td><td align="left" rowspan="1" colspan="1">P<sub>add</sub></td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Alleles</td><td align="left" rowspan="1" colspan="1">5172</td><td align="left" rowspan="1" colspan="1">2635</td><td align="left" rowspan="1" colspan="1">334</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="left" rowspan="1" colspan="1">46&#x000b1;8</td><td align="left" rowspan="1" colspan="1">46&#x000b1;8</td><td align="left" rowspan="1" colspan="1">46&#x000b1;8</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1">26.2&#x000b1;4.5</td><td align="left" rowspan="1" colspan="1">26.1&#x000b1;4.6</td><td align="left" rowspan="1" colspan="1">25.8&#x000b1;3.8</td><td align="left" rowspan="1" colspan="1">0.14</td></tr><tr><td align="left" rowspan="1" colspan="1">Whratio</td><td align="left" rowspan="1" colspan="1">0.86&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.86&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.86&#x000b1;0.09</td><td align="left" rowspan="1" colspan="1">0.43</td></tr><tr><td align="left" rowspan="1" colspan="1">waist (cm)</td><td align="left" rowspan="1" colspan="1">87&#x000b1;13</td><td align="left" rowspan="1" colspan="1">86&#x000b1;13</td><td align="left" rowspan="1" colspan="1">86&#x000b1;12</td><td align="left" rowspan="1" colspan="1">0.56</td></tr><tr><td align="left" rowspan="1" colspan="1">Height (cm)</td><td align="left" rowspan="1" colspan="1">172&#x000b1;9</td><td align="left" rowspan="1" colspan="1">172&#x000b1;9</td><td align="left" rowspan="1" colspan="1">172&#x000b1;9</td><td align="left" rowspan="1" colspan="1">0.91</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting serum triglyceride (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;1.4</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">1.3&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting serum cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">5.6&#x000b1;1.1</td><td align="left" rowspan="1" colspan="1">0.28</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting serum HDL cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">1.4&#x000b1;0.4</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Systolic bp (mmHg)</td><td align="left" rowspan="1" colspan="1">130&#x000b1;17</td><td align="left" rowspan="1" colspan="1">131&#x000b1;17</td><td align="left" rowspan="1" colspan="1">130&#x000b1;17</td><td align="left" rowspan="1" colspan="1">0.53</td></tr><tr><td align="left" rowspan="1" colspan="1">Diastolic bp (mmHg)</td><td align="left" rowspan="1" colspan="1">82&#x000b1;11</td><td align="left" rowspan="1" colspan="1">83&#x000b1;11</td><td align="left" rowspan="1" colspan="1">82&#x000b1;11</td><td align="left" rowspan="1" colspan="1">0.72</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma insulin (pmol/l)</td><td align="left" rowspan="1" colspan="1">42&#x000b1;28</td><td align="left" rowspan="1" colspan="1">41&#x000b1;27</td><td align="left" rowspan="1" colspan="1">41&#x000b1;25</td><td align="left" rowspan="1" colspan="1">0.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma insulin 30 min (pmol/l)</td><td align="left" rowspan="1" colspan="1">295&#x000b1;191</td><td align="left" rowspan="1" colspan="1">287&#x000b1;174</td><td align="left" rowspan="1" colspan="1">276&#x000b1;151</td><td align="left" rowspan="1" colspan="1">0.36</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma insulin 120 min (pmol/l)</td><td align="left" rowspan="1" colspan="1">218&#x000b1;215</td><td align="left" rowspan="1" colspan="1">215&#x000b1;216</td><td align="left" rowspan="1" colspan="1">217&#x000b1;191</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">HOMA-IR</td><td align="left" rowspan="1" colspan="1">10.6&#x000b1;7.9</td><td align="left" rowspan="1" colspan="1">10.4&#x000b1;7.8</td><td align="left" rowspan="1" colspan="1">10.1&#x000b1;6.8</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1">Insulinogenic Index</td><td align="left" rowspan="1" colspan="1">30&#x000b1;20</td><td align="left" rowspan="1" colspan="1">29&#x000b1;19</td><td align="left" rowspan="1" colspan="1">28&#x000b1;17</td><td align="left" rowspan="1" colspan="1">0.41</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma glucose (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;0.8</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;0.9</td><td align="left" rowspan="1" colspan="1">5.5&#x000b1;0.7</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma glucose 30 min (mmol/l)</td><td align="left" rowspan="1" colspan="1">8.7&#x000b1;1.9</td><td align="left" rowspan="1" colspan="1">8.7&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">8.7&#x000b1;1.8</td><td align="left" rowspan="1" colspan="1">0.94</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma glucose 120 min (mmol/l)</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;2.1</td><td align="left" rowspan="1" colspan="1">6.2&#x000b1;2.2</td><td align="left" rowspan="1" colspan="1">6.3&#x000b1;2.2</td><td align="left" rowspan="1" colspan="1">0.52</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting plasma C-peptide (pmol/l)</td><td align="left" rowspan="1" colspan="1">597&#x000b1;276</td><td align="left" rowspan="1" colspan="1">586&#x000b1;253</td><td align="left" rowspan="1" colspan="1">591&#x000b1;267</td><td align="left" rowspan="1" colspan="1">0.85</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma C-peptide 30 min(pmol/l)</td><td align="left" rowspan="1" colspan="1">2014&#x000b1;738</td><td align="left" rowspan="1" colspan="1">1988&#x000b1;676</td><td align="left" rowspan="1" colspan="1">1945&#x000b1;709</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1">Plasma C-peptide 120 min (pmol/l)</td><td align="left" rowspan="1" colspan="1">2314&#x000b1;1042</td><td align="left" rowspan="1" colspan="1">2301&#x000b1;982</td><td align="left" rowspan="1" colspan="1">2336&#x000b1;968</td><td align="left" rowspan="1" colspan="1">0.17</td></tr></tbody></table><table-wrap-foot><fn id="nt105"><p>Data presented as mean (SD). Analyses adjusted for age, gender, BMI, glucose tolerance (NGT, IFG, IGT and screen-detected untreated T2D).</p></fn><fn id="nt106"><p>T2D, type 2 diabetes; NGT, normal glucose tolerance; IFG, impaired fasting glucose; IGT, impaired glucose tolerance; add, additive; dom, dominant; res, recessive; bmi, body mass index; whratio, waist-to-hip ratio; hdl, high density lipoprotein; bp, blood pressure; HOMA-IR, insulin resistance according to HOMA model.</p></fn></table-wrap-foot></table-wrap><p>The two identified haplotype blocks of <italic>CHI3LI</italic> did not show any association with T2D (<xref ref-type="table" rid="pone-0005469-t005">Table 5</xref>).</p><table-wrap id="pone-0005469-t005" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0005469.t005</object-id><label>Table 5</label><caption><title><italic>CHI3LI</italic> haplotype association studies in relation to T2D.</title></caption><graphic id="pone-0005469-t005-5" xlink:href="pone.0005469.t005"/><table frame="hsides" rules="groups" alternate-form-of="pone-0005469-t005-5"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">SNPs</td><td align="left" rowspan="1" colspan="1">Haplotype</td><td align="left" rowspan="1" colspan="1">Frequency (&#x00025;), total sample</td><td align="left" rowspan="1" colspan="1">p value</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">rs4950928 | rs10399931</td><td align="left" rowspan="1" colspan="1">GT</td><td align="left" rowspan="1" colspan="1">0.1999</td><td align="left" rowspan="1" colspan="1">0.71</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CT</td><td align="left" rowspan="1" colspan="1">0.0345</td><td align="left" rowspan="1" colspan="1">0.98</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">CC</td><td align="left" rowspan="1" colspan="1">0.76398</td><td align="left" rowspan="1" colspan="1">0.74</td></tr><tr><td align="left" rowspan="1" colspan="1">rs6691378 | rs4950930 | rs12123883 | rs2486064 | rs2886117</td><td align="left" rowspan="1" colspan="1">GGTGA</td><td align="left" rowspan="1" colspan="1">0.00667</td><td align="left" rowspan="1" colspan="1">0.16</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GATGG</td><td align="left" rowspan="1" colspan="1">0.04281</td><td align="left" rowspan="1" colspan="1">0.47</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GGCAG</td><td align="left" rowspan="1" colspan="1">0.07954</td><td align="left" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GGTAG</td><td align="left" rowspan="1" colspan="1">0.35018</td><td align="left" rowspan="1" colspan="1">0.65</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">AGTGA</td><td align="left" rowspan="1" colspan="1">0.11792</td><td align="left" rowspan="1" colspan="1">0.46</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">GGTGG</td><td align="left" rowspan="1" colspan="1">0.40448</td><td align="left" rowspan="1" colspan="1">0.38</td></tr></tbody></table><table-wrap-foot><fn id="nt107"><p>Data show the association with T2D for the 2 haplotype blocks of 2 respectively 5 genotyped SNPs in <italic>CHI3LI</italic>. Haplotype tgSNPs were selected from the HapMap data using TAGGER.</p></fn><fn id="nt108"><p>T2D, type 2 diabetes; SNP, single nucleotide polymorphism.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s4"><title>Discussion</title><p>This is a large-scale and to our knowledge the first study of variation in <italic>CHI3LI</italic> in relation to T2D and pre-diabetic quantitative traits. <italic>CHI3LI</italic> encodes the inflammatory protein YKL-40 which previously has been found to be elevated in plasma from patients with T2D <xref ref-type="bibr" rid="pone.0005469-Rathcke2">&#x0005b;6&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005469-Rathcke3">&#x0005b;7&#x0005d;</xref> and from patients with T1D where it also correlates with increasing levels of albuminuria <xref ref-type="bibr" rid="pone.0005469-Rathcke4">&#x0005b;8&#x0005d;</xref>. In our study, we have exmained 11 tgSNPs covering the common variation (MAF&#x0003e;5&#x00025;) in <italic>CHI3LI</italic> including the SNPs rs10399931 and rs4950928 which previously have been found to contribute to interindividual variations in circulating YKL-40 levels in patients with sarcoidosis <xref ref-type="bibr" rid="pone.0005469-Kruit1">&#x0005b;9&#x0005d;</xref> and asthma <xref ref-type="bibr" rid="pone.0005469-Ober1">&#x0005b;11&#x0005d;</xref>, respectively. Furthermore, <italic>CHI3LI</italic> has been found to be a susceptibility gene for asthma, since rs4950928 is predictive of asthma, bronchial hyperresponsiveness and reduced lung function.</p><p>A total of 9438 individuals have been examined, but no significant association of rs10399931, rs4950928 or any of the other tgSNPs of <italic>CHI3LI</italic> were found with T2D or any of the intermediate T2D related quantitative traits. A borderline protective association with IGT was detected for rs12123883, but rs12123883 is a rare SNP with only few homozygotes and the protective association is most likely a chance finding. Furthermore, the p-value would not withstand correction for multiple testing considering the number of tests performed. On the same line, none of the two identified haplotype blocks showed any association with T2D.</p><p>In association analyses of rs10399931 and SNPs analysed in the DGI genome wide association scan study, rs10399931 is in LD with rs4950929 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.74) and rs946263 (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;0.78). Other correlations had r<sup>2</sup>-values&#x0003c;0.05. In the DGI genome wide association scan study, no significant associations of rs4950929 with any of the type 2 diabetic phenotypic traits were found, but the rs946263 G-allele was nominally found to be associated with T2D (p&#x0200a;&#x0003d;&#x0200a;0.027) <xref ref-type="bibr" rid="pone.0005469-Saxena1">&#x0005b;16&#x0005d;</xref>. rs946263, which is a synonymous SNP located &#x02212;9639 base pairs from the translational start site in <italic>CHI3LI</italic>, is also in perfect LD (r<sup>2</sup>&#x0200a;&#x0003d;&#x0200a;1.0) with rs4950928, which accounts for approximately 10&#x00025; of the variance in plasma YKL-40 levels in asthma patients <xref ref-type="bibr" rid="pone.0005469-Ober1">&#x0005b;11&#x0005d;</xref>. Beside the LD of rs10399931 and rs4950928 with rs946263, none of the examined SNPs or haplotype blocks of <italic>CHI3LI</italic> seem to be of any significance for the T2D diagnosis or any of the T2D related quantitative traits. Since the encoded inflammatory protein, YKL-40, of <italic>CHI3LI</italic> seems to be both a marker of inflammation and endothelial dysfunction <xref ref-type="bibr" rid="pone.0005469-Rathcke1">&#x0005b;5&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005469-Johansen1">&#x0005b;17&#x0005d;</xref> it is possible that it is the endothelial dysfunction and the later micro- and macrovascular complications of T2D that accounts for the elevated YKL-40 levels in T2D patients. In endothelial dysfunction, elevated YKL-40 levels seem to play a role in relation to cell migration, reorganization and tissue remodelling as a response to endothelial damage <xref ref-type="bibr" rid="pone.0005469-Shackelton1">&#x0005b;18&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005469-Millis1">&#x0005b;20&#x0005d;</xref>.</p><p>The possible assocation between YKL-40 and vascular damage is supported by the finding of an independent association between elevated circulating YKL-40 levels and increasing levels of albuminuria in T1D patients <xref ref-type="bibr" rid="pone.0005469-Rathcke4">&#x0005b;8&#x0005d;</xref>. Elevated plasma YKL-40 is also found to be associated with the presence and extent of coronary artery disease as assessed by coronary angiography <xref ref-type="bibr" rid="pone.0005469-Kucur1">&#x0005b;21&#x0005d;</xref> and just recently, YKL-40 levels have been found to be elevated in patients with myocardial infarction <xref ref-type="bibr" rid="pone.0005469-Nojgaard1">&#x0005b;22&#x0005d;</xref>. Furthermore, increasing YKL-40 levels do predict cardiovascular mortality in individuals without known DM or CHD after adjustment for known CV risk factors and markers <xref ref-type="bibr" rid="pone.0005469-Rathcke3">&#x0005b;7&#x0005d;</xref>.</p><p>Substantial evidence supports the notion that endothelial dysfunction and low-grade inflammation play a major pathophysiological role in the development of insulin resistance and the progression to manifest T2D <xref ref-type="bibr" rid="pone.0005469-Meigs1">&#x0005b;23&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005469-Ingelsson1">&#x0005b;29&#x0005d;</xref>. We have previously shown, that YKL-40 levels are elevated in patients with T2D where it correlates with insulin resistance as assessed by the HOMA model and with levels of triglycerides and non-esterified fatty acids <xref ref-type="bibr" rid="pone.0005469-Rathcke2">&#x0005b;6&#x0005d;</xref>. Since we found no association of any of the tgSNPs and surrogate markers of insulin resistance or the diabetic lipid profile in the present study, it does not seem to be any of these tgSNPs that explain the previously found correlation with these variables <xref ref-type="bibr" rid="pone.0005469-Rathcke2">&#x0005b;6&#x0005d;</xref>.</p><p>Multiple genes on different chromosomes may influence inflammatory biomarker levels and may have a potential role in the development of insulin resistance through a low-grade inflammatory state <xref ref-type="bibr" rid="pone.0005469-Dupuis1">&#x0005b;30&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0005469-Vickers1">&#x0005b;33&#x0005d;</xref>. In proximity of the YKL-40 encoding gene, locus 1q32.2 has been documented to influence the plasma levels of ICAM-1<xref ref-type="bibr" rid="pone.0005469-Dupuis1">&#x0005b;30&#x0005d;</xref>, an adhesion molecule well-documented to participate in endothelial dysfunction and the development of T2D <xref ref-type="bibr" rid="pone.0005469-Meigs1">&#x0005b;23&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0005469-Kolb1">&#x0005b;25&#x0005d;</xref>. However, association studies between YKL-40 and ICAM-1, either at protein or transcript levels, have not been conducted. Neither have association studies of variations of <italic>CHI3L1</italic> in relation to micro- or macrovascular conditions never been made.</p><p>In conclusion, both rs10399931 and rs4950928 are in high LD with rs946263 which is reported to associate with phenotypic traits of T2D in DGI <xref ref-type="bibr" rid="pone.0005469-Saxena1">&#x0005b;16&#x0005d;</xref>. However, neither rs1039991 nor rs4950928 nor any other tgSNPs of <italic>CHI3LI</italic> which were investigated in the present study are associated with T2D or T2D related quantitative traits including estimates of insulin resistance and dysregulated glucose homeostasis in the examined approximately 9500 Danes. Further studies are required to determine YKL-40 levels as a marker of inflammation in the prediabetic state and the role of <italic>CHI3LI</italic> in the pathogenesis of T2D.</p></sec><sec sec-type="supplementary-material" id="s5"><title>Supporting Information</title><supplementary-material content-type="local-data" id="pone.0005469.s001"><label>Table S1</label><caption><p>Case control association studies of 540 individuals with impaired fasting glucose (IFG) and 5302 glucose tolerant control participants in relation to the 11 tgSNPs of CHI3LI.</p><p>(0.08 MB DOC)</p></caption><media xlink:href="pone.0005469.s001.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0005469.s002"><label>Table S2</label><caption><p>Case control association studies of 830 individuals with impaired glucose tolerance (IGT) and 5302 glucose tolerant control participants in relation to the 11 tgSNPs of CHI3LI</p><p>(0.08 MB DOC)</p></caption><media xlink:href="pone.0005469.s002.doc" mimetype="application" mime-subtype="msword"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack><p>We wish to thank A. Forman, I.-L. Wantzin and M. Stendal for technical assistance and Michel Kristensen, Arne Nielsen and Grete Lademann for management and secretarial support.</p></ack><ref-list><title>References</title><ref id="pone.0005469-McCarthy1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>MI</given-names></name></person-group><year>2003</year><article-title>Growing evidence for diabetes susceptibility genes from genome scan data.</article-title><source>Curr Diab Rep</source><volume>3</volume><fpage>159</fpage><lpage>67</lpage><pub-id pub-id-type="pmid">12728642</pub-id></citation></ref><ref id="pone.0005469-McCarthy2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name></person-group><year>2006</year><article-title>Genetics of type 2 diabetes.</article-title><source>Curr Diab Rep</source><volume>6</volume><fpage>147</fpage><lpage>54</lpage><pub-id pub-id-type="pmid">16542626</pub-id></citation></ref><ref id="pone.0005469-McCarthy3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Zeggini</surname><given-names>E</given-names></name></person-group><year>2007</year><article-title>Genome-wide association scans for Type 2 diabetes: new insights into biology and therapy.</article-title><source>Trends Pharmacol Sci</source><volume>28</volume><fpage>598</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">17997168</pub-id></citation></ref><ref id="pone.0005469-Langefeld1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langefeld</surname><given-names>CD</given-names></name><name><surname>Wagenknecht</surname><given-names>LE</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Williams</surname><given-names>AH</given-names></name><name><surname>Hokanson</surname><given-names>JE</given-names></name><etal/></person-group><year>2004</year><article-title>Linkage of the metabolic syndrome to 1q23&#x02013;q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study.</article-title><source>Diabetes</source><volume>53</volume><fpage>1170</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">15047638</pub-id></citation></ref><ref id="pone.0005469-Rathcke1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name></person-group><year>2006</year><article-title>YKL-40, a new inflammatory marker with relation to insulin resistance and with a role in endothelial dysfunction and atherosclerosis.</article-title><source>Inflamm Res</source><volume>55</volume><fpage>221</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16955240</pub-id></citation></ref><ref id="pone.0005469-Rathcke2"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Johansen</surname><given-names>JS</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name></person-group><year>2006</year><article-title>YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance.</article-title><source>Inflamm Res</source><volume>55</volume><fpage>53</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16612564</pub-id></citation></ref><ref id="pone.0005469-Rathcke3"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Raymond</surname><given-names>I</given-names></name><name><surname>Kistorp</surname><given-names>C</given-names></name><name><surname>Hildebrandt</surname><given-names>P</given-names></name><name><surname>Faber</surname><given-names>J</given-names></name><etal/></person-group><year>2009</year><article-title>Low grade inflammation as measured by levels of YKL-40: Association with an increased overall and cardiovascular mortality rate in an elderly population.</article-title><source>Int J Cardiol.</source><comment>In Press</comment></citation></ref><ref id="pone.0005469-Rathcke4"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rathcke</surname><given-names>CN</given-names></name><name><surname>Persson</surname><given-names>F</given-names></name><name><surname>Tarnow</surname><given-names>L</given-names></name><name><surname>Rossing</surname><given-names>P</given-names></name><name><surname>Vestergaard</surname><given-names>H</given-names></name></person-group><year>2009</year><article-title>YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with Type 1 Diabetes and increases with levels of albuminuria.</article-title><source>Diabetes Care.</source><comment>In Press</comment></citation></ref><ref id="pone.0005469-Kruit1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kruit</surname><given-names>A</given-names></name><name><surname>Grutters</surname><given-names>JC</given-names></name><name><surname>Ruven</surname><given-names>HJ</given-names></name><name><surname>van Moorsel</surname><given-names>CC</given-names></name><name><surname>van den Bosch</surname><given-names>JM</given-names></name></person-group><year>2007</year><article-title>A CHI3L1 gene polymorphism is associated with serum levels of YKL-40, a novel sarcoidosis marker.</article-title><source>Respir Med</source><volume>101</volume><fpage>1563</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">17236752</pub-id></citation></ref><ref id="pone.0005469-Dixon1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dixon</surname><given-names>AL</given-names></name><name><surname>Liang</surname><given-names>L</given-names></name><name><surname>Moffatt</surname><given-names>MF</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Heath</surname><given-names>S</given-names></name><etal/></person-group><year>2007</year><article-title>A genome-wide association study of global gene expression.</article-title><source>Nat Genet</source><volume>39</volume><fpage>1202</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">17873877</pub-id></citation></ref><ref id="pone.0005469-Ober1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ober</surname><given-names>C</given-names></name><name><surname>Tan</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Possicj</surname><given-names>JD</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><etal/></person-group><year>2008</year><article-title>Effect of variation in CHI3L1 on serum YKL-40 level, risk of asthma, and lung function.</article-title><source>N Engl J Med</source><volume>358</volume><fpage>1682</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">18403759</pub-id></citation></ref><ref id="pone.0005469-Jorgensen1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jorgensen</surname><given-names>T</given-names></name><name><surname>Borch-Johnsen</surname><given-names>K</given-names></name><name><surname>Thomsen</surname><given-names>TF</given-names></name><name><surname>Ibsen</surname><given-names>H</given-names></name><name><surname>Glumer</surname><given-names>C</given-names></name><etal/></person-group><year>2003</year><article-title>A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99.</article-title><source>Eur J Cardiovasc Prev Rehabil</source><volume>10</volume><fpage>377</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">14663300</pub-id></citation></ref><ref id="pone.0005469-Alberti1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Alberti</surname><given-names>KG</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><year>1998</year><article-title>Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation.</article-title><source>Diabet Med</source><volume>15</volume><fpage>539</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">9686693</pub-id></citation></ref><ref id="pone.0005469-deBakker1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Bakker</surname><given-names>PI</given-names></name><name><surname>Yelensky</surname><given-names>R</given-names></name><name><surname>Pe'er</surname><given-names>I</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Daly</surname><given-names>MJ</given-names></name><etal/></person-group><year>2005</year><article-title>Efficiency and power in genetic association studies.</article-title><source>Nat Genet</source><volume>37</volume><fpage>1217</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">16244653</pub-id></citation></ref><ref id="pone.0005469-Purcell1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Purcell</surname><given-names>S</given-names></name><name><surname>Neale</surname><given-names>B</given-names></name><name><surname>Todd-Brown</surname><given-names>K</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name><name><surname>Ferreira</surname><given-names>MA</given-names></name><etal/></person-group><year>2007</year><article-title>PLINK: a tool set for whole-genome association and population-based linkage analyses.</article-title><source>Am J Hum Genet</source><volume>81</volume><fpage>559</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">17701901</pub-id></citation></ref><ref id="pone.0005469-Saxena1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saxena</surname><given-names>R</given-names></name><name><surname>Voight</surname><given-names>BF</given-names></name><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Burtt</surname><given-names>NP</given-names></name><name><surname>de Bakker</surname><given-names>PI</given-names></name><etal/></person-group><year>2007</year><article-title>Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels.</article-title><source>Science</source><volume>316</volume><fpage>1331</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17463246</pub-id></citation></ref><ref id="pone.0005469-Johansen1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Johansen</surname><given-names>JS</given-names></name></person-group><year>2006</year><article-title>Studies on serum YKL-40 as a biomarker in diseases with inflammation, tissue remodelling, fibroses and cancer.</article-title><source>Dan Med Bull</source><volume>53</volume><fpage>172</fpage><lpage>209</lpage><pub-id pub-id-type="pmid">17087877</pub-id></citation></ref><ref id="pone.0005469-Shackelton1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shackelton</surname><given-names>LM</given-names></name><name><surname>Mann</surname><given-names>DM</given-names></name><name><surname>Millis</surname><given-names>AJ</given-names></name></person-group><year>1995</year><article-title>Identification of a 38-kDa heparin-binding glycoprotein (gp38k) in differentiating vascular smooth muscle cells as a member of a group of proteins associated with tissue remodeling.</article-title><source>J Biol Chem</source><volume>270</volume><fpage>13076</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">7768902</pub-id></citation></ref><ref id="pone.0005469-Malinda1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Malinda</surname><given-names>KM</given-names></name><name><surname>Ponce</surname><given-names>L</given-names></name><name><surname>Kleinman</surname><given-names>HK</given-names></name><name><surname>Shackelton</surname><given-names>LM</given-names></name><name><surname>Millis</surname><given-names>AJ</given-names></name></person-group><year>1999</year><article-title>Gp38k, a protein synthesized by vascular smooth muscle cells, stimulates directional migration of human umbilical vein endothelial cells.</article-title><source>Exp Cell Res</source><volume>250</volume><fpage>168</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">10388530</pub-id></citation></ref><ref id="pone.0005469-Millis1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Millis</surname><given-names>AJ</given-names></name><name><surname>Hoyle</surname><given-names>M</given-names></name><name><surname>Kent</surname><given-names>L</given-names></name></person-group><year>1986</year><article-title>In vitro expression of a 38,000 dalton heparin-binding glycoprotein by morphologically differentiated smooth muscle cells.</article-title><source>J Cell Physiol</source><volume>127</volume><fpage>366</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">3086326</pub-id></citation></ref><ref id="pone.0005469-Kucur1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kucur</surname><given-names>M</given-names></name><name><surname>Isman</surname><given-names>FK</given-names></name><name><surname>Karadag</surname><given-names>B</given-names></name><name><surname>Vural</surname><given-names>VA</given-names></name><name><surname>Tavsanoglu</surname><given-names>S</given-names></name></person-group><year>2007</year><article-title>Serum YKL-40 levels in patients with coronary artery disease.</article-title><source>Coron Artery Dis</source><volume>18</volume><fpage>391</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17627189</pub-id></citation></ref><ref id="pone.0005469-Nojgaard1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nojgaard</surname><given-names>C</given-names></name><name><surname>Host</surname><given-names>NB</given-names></name><name><surname>Christensen</surname><given-names>IJ</given-names></name><name><surname>Poulsen</surname><given-names>SH</given-names></name><name><surname>Egstrup</surname><given-names>K</given-names></name><etal/></person-group><year>2008</year><article-title>Serum levels of YKL-40 increases in patients with acute myocardial infarction.</article-title><source>Coron Artery Dis</source><volume>19</volume><fpage>257</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">18480670</pub-id></citation></ref><ref id="pone.0005469-Meigs1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Rifai</surname><given-names>N</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name></person-group><year>2004</year><article-title>Biomarkers of endothelial dysfunction and risk of type 2 diabetes mellitus.</article-title><source>JAMA</source><volume>291</volume><fpage>1978</fpage><lpage>86</lpage><pub-id pub-id-type="pmid">15113816</pub-id></citation></ref><ref id="pone.0005469-Pickup1"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pickup</surname><given-names>JC</given-names></name></person-group><year>2004</year><article-title>Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.</article-title><source>Diabetes Care</source><volume>27</volume><fpage>813</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">14988310</pub-id></citation></ref><ref id="pone.0005469-Kolb1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kolb</surname><given-names>H</given-names></name><name><surname>Mandrup-Poulsen</surname><given-names>T</given-names></name></person-group><year>2005</year><article-title>An immune origin of type 2 diabetes?</article-title><source>Diabetologia</source><volume>48</volume><fpage>1038</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">15864529</pub-id></citation></ref><ref id="pone.0005469-Eckel1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eckel</surname><given-names>RH</given-names></name><name><surname>Grundy</surname><given-names>SM</given-names></name><name><surname>Zimmet</surname><given-names>PZ</given-names></name></person-group><year>2005</year><article-title>The metabolic syndrome.</article-title><source>Lancet</source><volume>365</volume><fpage>1415</fpage><lpage>28</lpage><pub-id pub-id-type="pmid">15836891</pub-id></citation></ref><ref id="pone.0005469-Festa1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Festa</surname><given-names>A</given-names></name><name><surname>Hanley</surname><given-names>AJ</given-names></name><name><surname>Tracy</surname><given-names>RP</given-names></name><name><surname>D'Agostino</surname><given-names>R</given-names><suffix>Jr</suffix></name><name><surname>Haffner</surname><given-names>SM</given-names></name></person-group><year>2003</year><article-title>Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion.</article-title><source>Circulation</source><volume>108</volume><fpage>1822</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">14517163</pub-id></citation></ref><ref id="pone.0005469-Rutter1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rutter</surname><given-names>MK</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Sullivan</surname><given-names>LM</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></name><name><surname>Wilson</surname><given-names>PW</given-names></name></person-group><year>2004</year><article-title>C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study.</article-title><source>Circulation</source><volume>110</volume><fpage>380</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">15262834</pub-id></citation></ref><ref id="pone.0005469-Ingelsson1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Hulthe</surname><given-names>J</given-names></name><name><surname>Lind</surname><given-names>L</given-names></name></person-group><year>2008</year><article-title>Inflammatory markers in relation to insulin resistance and the metabolic syndrome.</article-title><source>Eur J Clin Invest</source><volume>38</volume><fpage>502</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18489581</pub-id></citation></ref><ref id="pone.0005469-Dupuis1"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Larson</surname><given-names>MG</given-names></name><name><surname>Vasan</surname><given-names>RS</given-names></name><name><surname>Massaro</surname><given-names>JM</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><etal/></person-group><year>2005</year><article-title>Genome scan of systemic biomarkers of vascular inflammation in the Framingham Heart Study: evidence for susceptibility loci on 1q.</article-title><source>Atherosclerosis</source><volume>182</volume><fpage>307</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">16159603</pub-id></citation></ref><ref id="pone.0005469-Pantsulaia1"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pantsulaia</surname><given-names>I</given-names></name><name><surname>Trofimov</surname><given-names>S</given-names></name><name><surname>Kobyliansky</surname><given-names>E</given-names></name><name><surname>Livshits</surname><given-names>G</given-names></name></person-group><year>2002</year><article-title>Genetic and environmental influences on IL-6 and TNF-alpha plasma levels in apparently healthy general population.</article-title><source>Cytokine</source><volume>19</volume><fpage>138</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">12242080</pub-id></citation></ref><ref id="pone.0005469-deMaat1"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>de Maat</surname><given-names>MP</given-names></name><name><surname>Bladbjerg</surname><given-names>EM</given-names></name><name><surname>Hjelmborg</surname><given-names>JB</given-names></name><name><surname>Bathum</surname><given-names>L</given-names></name><name><surname>Jespersen</surname><given-names>J</given-names></name><etal/></person-group><year>2004</year><article-title>Genetic influence on inflammation variables in the elderly.</article-title><source>Arterioscler Thromb Vasc Biol</source><volume>24</volume><fpage>2168</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">15345506</pub-id></citation></ref><ref id="pone.0005469-Vickers1"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vickers</surname><given-names>MA</given-names></name><name><surname>Green</surname><given-names>FR</given-names></name><name><surname>Terry</surname><given-names>C</given-names></name><name><surname>Mayosi</surname><given-names>BM</given-names></name><name><surname>Julier</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein.</article-title><source>Cardiovasc Res</source><volume>53</volume><fpage>1029</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11922913</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This study was supported by grants from Novo Nordisk and the European Union (InterAct, grant LSHMCT-2006-037197; EUGENE2, grant LSHM-CT-2004-512013), the Research Foundation of Herlev Hospital; the Research Foundation of Copenhagen County; the Danish Medical Research Council and the Swedish Research Council (J.H.), Timber Merchant Vilhelm Bangs Foundation; Aase and Ejnar Danielsens Foundation and The Danish Diabetes Association. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 